Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
goserelin
- Development stage
- Approved
- Lead developer
- AstraZeneca
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous
01
Overview
Goserelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH, also known as luteinizing hormone-releasing hormone). It acts as a potent inhibitor of pituitary gonadotropin secretion by overstimulating the GnRH receptor, leading to downregulation and suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release. This results in decreased production of sex hormones—testosterone in men and estradiol in women—to castrate or postmenopausal levels. Goserelin is primarily used for the treatment of prostate cancer, breast cancer (especially in pre- and perimenopausal women), endometriosis, uterine fibroids, dysfunctional uterine bleeding (as an endometrial-thinning agent prior to ablation), and for assisted reproduction protocols. It is administered as a subcutaneous implant[1][3][5][7].
- Brand names
- ZoladexZoladex 3-MonthZoladex3-MonthZoladex-3-Month
- Other names
- goserelina
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on goserelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on goserelin.